Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.31 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22100181 | 0.90 | MAPT (0.39) | MAPTSMN1; SMN2GAAKDM4ERAD52 | |
| SCHEMBL22074251 | 0.88 | MAPT (0.38) | MAPTSMN1; SMN2GAAKDM4ERAD52 | |
| SCHEMBL22133009 | 0.81 | MAPT (0.42) | MAPTSMN1; SMN2GAAKDM4ERAD52 | |
| SCHEMBL22100183 | 0.81 | DRD2 (0.36) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL22074309 | 0.73 | SMN1; SMN2 (0.40) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL20180555 | 0.68 | KDM4E (0.64) | MAPTSMN1; SMN2GAAKDM4ERAD52 | |
| SCHEMBL17875588 | 0.68 | MAPT (0.46) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL20041209 | 0.65 | CASP3 (0.37) | ALDH1A1HTT | |
| SCHEMBL20865773 | 0.65 | MAPT (0.41) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL10020845 | 0.64 | ALDH1A1 (0.36) | MAPTSMN1; SMN2GAAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BIOPHAGY INC (US) | 2021-12-28 | — | — | US | disclosed |
| WO-2020131924-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | Biophagy, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BIOPHAGY INC (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BECN1, ATG7, SQSTM1 | MAPT 33/4885SMN1; SMN2 440/4885GAA 15/4885 |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BECN1, ATG7, SQSTM1 | MAPT 33/4885SMN1; SMN2 440/4885GAA 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.